Cannasat Therapeutics Announces Closing of Private Placement
MarketWire, March 18, 2022
TORONTO – Cannasat Therapeutics Inc. (CTH - TSXV) ("Cannasat") is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units") effective March 14, 2008.
Cannasat issued an aggregate of 3,333,333 Units at a price of C$0.15 per Unit raising gross proceeds of C$500,000. Each Unit consists of one common share one share purchase warrant. Each share purchase warrant entitles the holder to acquire one common share at a price of C$0.20 for a period ending on the earlier of 12 months from the closing date, and a period ending 20 days after prior written notice from Cannasat that the closing price of its shares on the principal stock exchange of Cannasat has been at least C$0.30 per share for 20 consecutive trading days.
The common shares issued under the Private Placement are subject to a hold period of four months expiring on July 14, 2008.
The proceeds from the offering will be used to fund Cannasat’s ongoing research and development activities, including further Phase 1 clinical testing for CAT 310, as well as continued advanced formulation work for CAT 320. CAT 310 is a sublingual THC (delta-9-tetrahydrocannabinol) tablet for the treatment of neuropathic pain and other conditions. CAT 320 is a CBD (cannabidiol) tablet for the treatment of anxiety and other mood disorders.
Cash commissions in the total amount of C$28,436 were paid in connection with subscribers for Units.
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.
About Cannasat Therapeutics
Founded in 2004, Cannasat is clinical stage pharmaceutical research and development company trading on the Toronto Venture Exchange (CTH-V). Cannasat is developing cannabinoid-based pharmaceutical products using proprietary formulation and drug delivery technologies. Cannabinoids have broad therapeutic applications that are believed to include the treatment of neuropathic pain, chronic pain, depression, anxiety and movement disorders. More information about Cannasat is available at www.cannasat.com.
Contact Information
Cannasat Therapeutics Inc.
Andrew Williams
COO & CFO
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]
www.cannasat.com
